The PIK3CA mutation profile has prognostic significance and is potentially predictive for the response to agents targeting the PI3K pathway 8 Similarly, Pailler et al. observed considerable heterogeneity in ROS1-gene abnormalities in CTCs from non-small cell lung cancer (NSCLC), which could explain the mechanism by which tumor cells can escape sensitivity to ROS1-inhibitor therapy 16. This evidence concerns the gene PIK3CA and non-small cell lung carcinoma.